Moving
Seattle Sounders vs Real Salt Lake: Regulation Tim… Reg Time: Draw 1-1 97% ▲+86Which company has the best AI model on LiveBench (… Google 89% ▲+81Seattle vs Salt Lake Tie 96% ▲+73Seattle Sounders FC vs. Real Salt Lake Draw (Seattle Sounders FC vs. Real Salt Lake) 96% ▲+71Third-best Code Arena WebDev AI Lab end of November? OpenAI 77% ▲+682026 Midterms: U.S. House turnout? 115 to 119.99 million 32% ▼−47Who will join Trump at APEC in China? Yes 16% ▼−46BC Lokomotiv Kuban vs Dinamo Vladivostok BC Lokomotiv Kuban 89% ▲+42Players Era 8 Championship: Houston vs Kansas Houston 96% ▲+40Fear & Greed Index on Nov 20, 2026? Extreme Fear 81% ▲+39The Rsm Classic: Top 20 Finishers Michael Thorbjornsen 71% ▲+37Who will Trump meet with by November 30? Elon Musk 43% ▼−32Who will Trump speak to by November 30? Volodymyr Zelenskyy 71% ▲+32VCU Rams vs. Santa Clara Broncos Santa Clara Broncos 83% ▲+31
KalshiCloses January 1, 2027

Will the FDA approve any psychedelic substance for medical use this year?

The market puts it at 15% — about 2 in ten — on Kalshi, as of Nov 20, 05:17 UTC. It's down 5 points in the last 24 hours.

Yes 15% ▼ 5 pts · 24h

The odds

as of Nov 20, 05:17 UTC
  • Chance of yes 15% −5
Traded today$779
Traded in all$449K
Yes, 7 days−1.5 pts

Yes, the last 7 days

Kalshi price
25%50%75%Nov 12Nov 2015%

Nov 13: 17% · Nov 14: 17% · Nov 15: 19% · Nov 16: 16% · Nov 17: 23% · Nov 18: 16% · Nov 19: 15% · Nov 20: 15%

How it resolves

Kalshi's rule, word for word
If the FDA approves any psychedelic substance for medical use for marketing before Jan 1, 2027, then the market resolves to Yes. Psychedelic drugs include: LSD, Psilocybin, DMT, Mescaline, MDMA, MDA, PCP, DXM, Ibogaine, Salvia divinorum, 2C family, and Ayahuasca. Important information: For purposes of this Contract: The listed substances are illustrative, not exhaustive. Approval of any other substance commonly recognized in scientific or FDA documentation as a psychedelic, hallucinogen, or entactogen (for example, psilocin, 5-MeO-DMT, methylone, or 2C-, DOx-, or NBOMe-family compounds) may also satisfy the Payout Criterion. "Approval for medical use" means an FDA approval letter for an NDA or BLA authorizing marketing of a drug or biologic for human medical use in the United States, where a listed (or otherwise qualifying) psychedelic substance is an active pharmaceutical ingredient of the approved product. Complete Response Letters, tentative approvals, Emergency Use Authorizations, expanded access or compassionate use authorizations, and approvals limited to export do not satisfy the Payout Criterion. Combination products. Approval of a combination drug product satisfies the Payout Criterion only if at least one active ingredient is a listed (or otherwise qualifying) psychedelic substance and that psychedelic active ingredient has not previously been approved by the FDA via NDA or BLA for any human medical indication. By way of example, an FDA approval of AXS-05 (a combination of dextromethorphan and bupropion) for a new indication does not satisfy the Payout Criterion, because both active ingredients were FDA-approved prior to Issuance. New indications for previously-approved substances. An FDA approval (including via supplemental NDA or supplemental BLA) of a new medical indication, dosage, or formulation for a substance whose active pharmaceutical ingredient was already approved by the FDA via NDA or BLA prior to Issuance does not satisfy the Payout Criterion.

Settlement sources: FDA; U.S. Food and Drug Administration.

See it on Kalshi ↗

Tech & science

More markets like this

All →